Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Nucala injection is prescribed for eosinophilic asthma and certain other conditions. It’s important to administer the injection safely and correctly so that the medication will be effective.

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab ... Previously approved in China for severe eosinophilic asthma in adult and adolescent individuals of ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab ... Previously approved in China for severe eosinophilic asthma in adult and adolescent ...

GSK's Nucala approved in China for CRSwNP ... for adults and adolescents aged 12 years and older with severe eosinophilic asthma as well as for adults with eosinophilic granulomatosis with ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal ... aged 12 years and older with severe eosinophilic asthma as well as for adults ...

The new versions were approved in the US in June. Nucala was the first IL-5 inhibitor to be approved for eosinophilic asthma in 2015, making rapid headway in this severe form of the respiratory ...

Nucala's latest indication marked its third approval in China for IL-5-mediated conditions. The therapy is already authorised for use in severe eosinophilic asthma and eosinophilic granulomatosis ...

GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal ... adults and adolescents aged 12 years and older with severe ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab ... aged 12 years and older with severe eosinophilic asthma as well as for adults ...